Aclaris Therapeutics Inc (ACRS)

15.12 -0.58  -3.69% NASDAQ Jul 26, 20:00 USD
View Full Chart
Price Chart
View All ACRS News

News

View All Events

Events

Date Type Description
11/04/2021 17:00 EST Earnings Calls Q3 2021 Earnings Call
08/06/2021 Earnings Results Q2 2021 Earnings Results
06/03/2021 09:00 EST AGM 2020 Annual General Meeting
05/07/2021 Earnings Results Q1 2021 Earnings Results
02/25/2021 Earnings Results Q4 2020 Earnings Results
11/04/2020 Earnings Results Q3 2020 Earnings Results
08/07/2020 Earnings Results Q2 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are ATI-450, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
  • URL: https://www.aclaristx.com
  • Investor Relations URL: https://www.aclaristx.com/#!investors/juser
  • HQ State/Province: Pennsylvania
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Aug. 06, 2021
  • Last Earnings Release: May. 07, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Top Fund Holders

Symbol Name Weighting
BRSIX Bridgeway Ultra-Small Company Market 1.46%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.